Printer Friendly

Jacobson Resonance Enterprises, Inc. (OTC-BB-JRSE) Announces Near Completion of Successful Clinical Trials in Pain Relief of Cirvico-Arthrosis.

BOYNTON BEACH, Fla., and GENEVA -- In a joint communique, Jacobson Resonance Enterprises, Inc. (BULLETIN BOARD: JRSE) and Serrato Enterprises Serrato Europe, S.a.r.l., announced today that the double blind clinical trials in pain relief of cervico-arthrosis are proceeding in Spain with positive results.

Dr. Pedro Alonzo, Chief Investigator for Hospital Costa del Sol in Marbella, Spain, announced that, "The clinical trials are nearing completion and the effectiveness of the Jacobson Resonator is indeed impressive. It is expected that these clinical trials will be completed by the end of the year with the findings being submitted to the Spanish Health Ministry for their approval."

Alfonso Serrato, President and CEO of JRSE said, "Obtainment of the CE-MARK in cevico-arthrosis expands the commercial applications of the Jacobson Resonator to an additional 19 million people that are afflicted with this condition throughout the European Union. We are very pleased with the clinical results where the efficacy of the resonator in palliating pain has been successfully proven. We expect CE-MARK approval early First Quarter 2002.

"The proof of our results and the acceptance of our innovative technology is growing and attesting for 'A New Medical Standard' for treating and eliminating pain that our company is committed to."

Mr. Serrato closed by saying, "Over the coming weeks, we expect to announce our commercial distribution and marketing initiatives throughout the rest of the European Union."

CE-MARK approval for the alleviation of pain of the human osteoarthritic knee was granted earlier this year and the Health Canada licensing clearance for the treatment of all forms of pain throughout the body have made 2001 a turnaround year. JRSE has successfully transitioned from a research and development company to one of global commercial operations.

Serrato Enterprises-Serrato Europe will commence with the distribution and sales of resonators in Latin America during the first quarter of 2002. JRSE remains focused on becoming the world leader in bioelectromagnetics and the premier company in the eradication of human suffering.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The matters covered by such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements of the Company to differ materially from those contemplated or implied by such forward-looking statements. For further information, contact Frank Chaviano at (561) 752-4141.

MAKE YOUR OPINION COUNT - Click Here

http://tbutton.prnewswire.com/prn/11690X78764386

Contact: Frank Chaviano of Jacobson Resonance, +1-561-752-4141

Website: http://www.jrse.com/
COPYRIGHT 2001 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2001 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 10, 2001
Words:419
Previous Article:Tech Data Closes Sale of $250 Million in Convertible Subordinated Debentures.
Next Article:Rogers Cable Selects Motorola PurePixel(TM) Technology for Next-Generation Fiber Distribution Network; High-Quality Video Compression Key to Meeting...


Related Articles
Jacobson Resonance Enterprises Announces Results of the Final Report from European Clinical Trials on the Effects of the Jacobson Resonator In...
Jacobson Resonator Demonstrates Promising New Technology For Pain Relief From Bone And Joint Disorders.
Jacobson Resonance Enterprises, Inc. (OTC-BB-JRSE) Appoints New Vice President.
Jacobson Resonance Enterprises, Inc. (OTC-BB-JRSE) Executes Licensing With Bio Resonance Technology for Distribution and Manufacturing in Canada.
Jacobson Resonance Enterprises Inc. (OTC-BB-JRSE) Projects and Anticipates a Revenue Stream of $ 5.5 to $ 8.5 Million in Royalty Revenues from...
JACOBSON RESONANCE ENTERPRISES INC.
Dr. Jerry I. Jacobson, Founder of Jacobson Resonance Enterprises, Inc. (OTC-BB-JRSE) Spearheads Opening of Canadian Bio Resonance Pain Relief Centers.
Bio Resonance Technology, Inc. of Canada Licenses Opening of Pain Relief Facility Using Jacobson Resonators at Calgary's Holy Cross Centre.
Jacobson Resonance Enterprises, Inc. (OTC-BB-JRSE) Announces Bio-Resonance Technology, Inc. Receives Health Canada License to Alleviate All Types of...
Jacobson Resonance Enterprises, Inc. (OTC-BB-JRSE) Announces Preliminary Research Findings in Breast Cancer Cells From the College of Veterinary...

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters